Latest News on SGRY

Financial News Based On Company


Advertisement
Advertisement

Surgery Partners doubles consent fee for senior notes solicitation

https://www.streetinsider.com/Corporate+News/Surgery+Partners+doubles+consent+fee+for+senior+notes+solicitation/27366755.html
Surgery Partners' indirect subsidiary, Surgery Center Holdings, Inc., has increased the consent fee for its $1.225 billion aggregate principal amount of 7.250% Senior Notes due 2032. The fee has doubled from $2.50 to $5.00 per $1,000 in principal amount for valid consents. The solicitation is set to expire on November 20, 2026, and payment is contingent on receiving consents from a majority of noteholders.

Surgery Partners raises consent fee for noteholders to $5 per $1,000

https://ca.investing.com/news/stock-market-news/surgery-partners-raises-consent-fee-for-noteholders-to-5-per-1000-93CH-4966727
Surgery Partners, Inc. (NASDAQ:SGRY) has increased the consent fee for holders of its 7.250% Senior Notes due 2032 from $2.50 to $5.00 per $1,000 in principal amount. This fee is offered in exchange for soliciting consents for proposed amendments to the indenture governing the notes. The consent solicitation is set to expire on Thursday, and the payment is contingent upon receiving consents from a majority of noteholders.

Surgery Partners, Inc. Announces Increased Consent Fee in Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032

https://www.manilatimes.net/2026/11/18/tmt-newswire/globenewswire/surgery-partners-inc-announces-increased-consent-fee-in-consent-solicitation-relating-to-surgery-center-holdings-incs-7250-senior-notes-due-2032/2473049
Surgery Partners, Inc. announced an increase in the consent fee for its consent solicitation concerning Surgery Center Holdings, Inc.'s 7.250% Senior Notes due 2032. The fee has been raised from $2.50 to $5.00 per $1,000 principal amount for holders who validly deliver consents by the November 20, 2026, expiration time. This amendment aims to secure the necessary majority consent for proposed changes to the indenture governing the notes.

SGRY Merger Investigation: Surgery Partners Investigated Over $23.50 per Share Take-Private Merger – Contact BFA Law if You Hold Shares

https://www.mycarrollcountynews.com/online_features/press_releases/article_8e397187-0be5-57a3-89c2-135e50322772.html
Bleichmar Fonti & Auld LLP (BFA Law) is investigating the proposed take-private merger of Surgery Partners, Inc. (NASDAQ: SGRY) by Bon Secours Mercy Health, Inc. for $23.50 per share. The investigation focuses on potential breaches of fiduciary duty, as Surgery Partners' largest shareholder, Bain Capital, will roll over its equity while public stockholders are cashed out. BFA Law encourages current Surgery Partners stockholders to contact the firm to discuss their legal options regarding the fairness of the merger terms.

SHAREHOLDER NOTICE: Kaskela Law Firm Investigates Fairness of Proposed $25.00 Per Share Buyout Offer – Fair Price or Inadequately Low for Surgery Partners Inc. (SGRY) Shares?

https://www.wboc.com/online_features/press_releases/shareholder-notice-kaskela-law-firm-investigates-fairness-of-proposed-25-00-per-share-buyout-offer/article_e90ebd27-cbf8-5766-a122-054e85247adb.html
Kaskela Law Firm is investigating the proposed buyout of Surgery Partners, Inc. (SGRY) by HealthSpan Partners for $25.00 per share. The firm aims to determine if this offer is unfairly low, noting that several stock analysts had previously set price targets exceeding $28.00 for SGRY shares. Shareholders are encouraged to contact Kaskela Law for information regarding their legal rights.
Advertisement

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Stockholders of an Investigation into the Fairness of the Acquisition of Surgery Partners, Inc. (SGRY)

https://www.prnewswire.com/news-releases/shareholder-alert-levi--korsinsky-llp-notifies-stockholders-of-an-investigation-into-the-fairness-of-the-acquisition-of-surgery-partners-inc-sgry-302941147.html
Levi & Korsinsky, LLP has launched an investigation into the fairness of HealthSpan Partners' acquisition of Surgery Partners, Inc. (SGRY). Stockholders who purchased shares prior to October 23, 2026, are expected to receive $23.50 per share in cash. The law firm is encouraging affected shareholders to contact them for more information regarding the investigation.

SURGERY PARTNERS, INC. INVESTOR ALERT: Scott+Scott

https://www.globenewswire.com/news-release/2026/11/16/3404157/0/en/surgery-partners-inc-investor-alert-scott-scott-attorneys-at-law-llp-investigates-surgery-partners-inc-s-directors-for-breach-of-fiduciary-duties-sgry.html
Scott+Scott Attorneys at Law LLP has initiated an investigation into Surgery Partners, Inc. (NASDAQ: SGRY) regarding whether its directors breached fiduciary duties by approving a buyout by HealthSpan Partners for an allegedly inadequate price of $23.50 per share. The firm is encouraging shareholders of Surgery Partners common stock to join their investigation if they believe they have suffered damages.

SGRY: Surgery Partners Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

https://www.quantisnow.com/insight/surgery-partners-inc-filed-sec-form-8-k-regulation-fd-disclosure-6792315
Surgery Center Holdings, a subsidiary of Surgery Partners, has filed an SEC Form 8-K regarding a consent solicitation for its $1.225 billion 7.250% Senior Notes due 2032. This action is related to the company's pending merger with Spyglass Topco, LLC and Bon Secours Mercy Health. Noteholders who consent to proposed amendments will receive a $2.50 cash payment per $1,000 of principal, avoiding a change of control offer that would require repurchasing notes at 101% of principal.

Bon Secours Mercy Health bumps up offer for majority stake in Surgery Partners to $6B valuation

https://www.fiercehealthcare.com/providers/bon-secours-mercy-health-acquire-majority-stake-surgery-partners
Bon Secours Mercy Health has increased its offer to acquire a majority stake in Surgery Partners to a $6 billion valuation, or $25 per share, up from the initial $5.7 billion. This revised bid comes after Surgery Partners received an unsolicited $28 per share offer from a third party, reportedly UnitedHealth, which was rejected due to concerns about deal complexity. The transaction, expected to close in early 2027, aims to expand Bon Secours' outpatient surgical care platforms significantly.

HealthSpan Partners ups Surgery Partners offer to $6B after rival bid

https://www.healthcaredive.com/news/healthspan-partners-ups-surgery-partners-offer-to-6b-after-rival-bid/874313/
HealthSpan Partners, an affiliate of Bon Secours Mercy Health, increased its offer to acquire Surgery Partners to $6 billion, up from $5.7 billion, after the surgical facility network received an unsolicited bid from an undisclosed rival, reportedly UnitedHealth. The new terms offer Surgery Partners shareholders $25.00 per share, with potential additional monthly payments if the deal, expected to close in Q1 next year, is delayed past March 1. Surgery Partners stated the rival bid, while higher at $28.00 per share, would have taken "materially longer to close" and risked regulatory delays.
Advertisement

Surgery Partners delivers 68% return after Fair Value spotted opportunity

https://www.investing.com/news/investment-ideas/surgery-partners-delivers-68-return-after-fair-value-spotted-opportunity-93CH-5014747
InvestingPro's Fair Value models identified Surgery Partners, Inc. (NASDAQ:SGRY) as significantly undervalued in November 2025 when it was trading at $15.75. Investors who acted on this analysis saw a 67.94% return within twelve months, with shares reaching $26.45, exceeding the projected 52% upside. This case study demonstrates the effectiveness of multi-faceted valuation methodologies in identifying mispriced stocks and informing investment decisions.

Surgery Partners, Inc. Announces Third Quarter 2026 Results

https://www.quantisnow.com/insight/surgery-partners-inc-announces-third-quarter-2026-results-6781348
Surgery Partners, Inc. announced its third-quarter 2026 results, reporting an 0.8% decrease in revenue to $815.3 million and a net loss of $21.1 million. The company also confirmed an amended merger agreement with HealthSpan Partners, increasing the cash consideration to $25.00 per share, with the deal expected to close in Q1 2027. Due to the pending merger, Surgery Partners will cease providing forward-looking guidance and will not hold an earnings call.

Form DEFA14A Surgery Partners, Inc.

https://www.streetinsider.com/SEC+Filings/Form+DEFA14A+Surgery+Partners%2C+Inc./27312634.html
Surgery Partners, Inc. has filed an Amendment to its Agreement and Plan of Merger, increasing the merger consideration to $25.00 per share in cash for its common stock. The amendment also introduces a "Ticking Fee" for stockholders if the merger isn't completed by March 1, 2027, and revises regulatory efforts covenants and the Company Termination Fee. These changes are detailed in a Form 8-K filing and a related press release.

Surgery Partners Raises Buyout Price to $25 Per Share in Amended Merger Deal

https://www.tradingview.com/news/tradingview:43d320309203a:0-surgery-partners-raises-buyout-price-to-25-per-share-in-amended-merger-deal/
Surgery Partners (SGRY) has amended its merger agreement with Spyglass Topco, an affiliate of Bon Secours Mercy Health, increasing the cash acquisition price to $25 per share. The amendment also includes monthly payments to shareholders if the merger isn't closed by March 1, 2027, strengthens the buyer's regulatory obligations, and increases the termination fee. The original SEC filing was made on November 9, 2026.

SGRY: Surgery Partners Inc. filed SEC Form 8-K: Entry into a...

https://quantisnow.com/insight/surgery-partners-inc-filed-sec-form-8-k-entry-into-a-6780672
Surgery Partners Inc. has amended its merger agreement with HealthSpan Partners, increasing the cash price to $25.00 per share, with potential additional ticking fees of up to $1.61 per share if the deal closes after March 1, 2027. This amendment followed an unsolicited $28.00 per share proposal from a third party. The board recommends stockholders approve the revised agreement, which values the enterprise at approximately $6.0 billion.
Advertisement

Why is Surgery Partners (SGRY) stock rocketing higher today

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-9-why-is-surgery-partners-sgry-stock-rocketing-higher-today
Shares of Surgery Partners (NASDAQ: SGRY) surged 12% following an amended merger agreement with HealthSpan Partners, increasing the buyout consideration to $25 per share in cash, valuing the company at up to $6.0 billion. The revised deal includes potential additional ticking fees for non-Bain Capital stockholders if the transaction closes after March 1, 2027, and the board has unanimously recommended approval. This comes after a previous agreement valuing the company at $5.7 billion, with the stock now reaching a new 52-week high.

SGRY Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Surgery Partners to HealthSpan Partners

https://www.streetinsider.com/Globe+Newswire/SGRY+Alert%3A+Monsey+Firm+of+Wohl+%26amp%3B+Fruchter+Investigating+Fairness+of+the+Proposed+Sale+of+Surgery+Partners+to+HealthSpan+Partners/27287523.html
The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Surgery Partners, Inc. (NASDAQ: SGRY) to HealthSpan Partners for $23.50 per share in cash. The investigation focuses on whether the Special Committee that approved the sale was independent and disinterested, particularly since Surgery Partners' largest stockholder, Bain Capital, will roll over its shares into the new entity while public stockholders are cashed out. Wohl & Fruchter encourages SGRY stockholders with concerns to contact them.

SGRY Shareholder Notice: Surgery Partners $23.50 per Share Merger Under Investigation on Behalf of Shareholders

https://www.morningstar.com/news/pr-newswire/20261103ny87052/sgry-shareholder-notice-surgery-partners-2350-per-share-merger-under-investigation-on-behalf-of-shareholders
Bleichmar Fonti & Auld LLP (BFA Law) is investigating the proposed $23.50 per share merger of Surgery Partners (NASDAQ: SGRY) by Bon Secours Mercy Health, Inc. The investigation focuses on potential breaches of fiduciary duty, as Surgery Partners' largest shareholder, Bain Capital, is rolling over its equity into the post-merger entity while other stockholders are being cashed out. BFA Law is questioning whether the $23.50 per share price is fair for public stockholders and is encouraging current shareholders to contact the firm regarding their legal options.

SGRY Shareholder Notice: Surgery Partners $23.50 per Share Merger Under Investigation on Behalf of Shareholders

https://www.prnewswire.com/news-releases/sgry-shareholder-notice-surgery-partners-23-50-per-share-merger-under-investigation-on-behalf-of-shareholders-302926967.html
Bleichmar Fonti & Auld LLP (BFA Law) is investigating the proposed $23.50 per share merger of Surgery Partners, Inc. (NASDAQ: SGRY) by Bon Secours Mercy Health, Inc. The investigation focuses on potential breaches of fiduciary duty, particularly because Surgery Partners' largest shareholder, Bain Capital, will roll over its equity into the post-merger entity while public shareholders are cashed out. BFA Law encourages current Surgery Partners stockholders to contact the firm to discuss their legal options regarding the fairness of the per-share price and compliance with Delaware law.

Bon Secours Mercy Health agrees to buy surgery center chain Surgery Partners for $5.7 billion

https://www.marketscale.com/industries/healthcare/bon-secours-mercy-health-agrees-to-buy-surgery-center-chain-surgery-partners-for-57-billion
Bon Secours Mercy Health, through its affiliate HealthSpan Partners, has agreed to acquire Surgery Partners in a $5.7 billion deal, taking the surgery center chain private. This acquisition, expected to close in Q1 2027, will significantly expand Bon Secours' presence in the outpatient surgery market, building on Surgery Partners' $3.31 billion revenue in 2025. The deal is partly financed by new debt and sees Bain Capital, a current minority owner, rolling its 39% stake into HealthSpan Partners equity, maintaining a significant involvement.
Advertisement

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Surgery Partners, Inc. (NASDAQ: SGRY)

https://www.morningstar.com/news/pr-newswire/20261028dc82946/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-surgery-partners-inc-nasdaq-sgry
Monteverde & Associates PC, a class action firm, has announced an investigation into Surgery Partners, Inc. (NASDAQ: SGRY) concerning its sale to HealthSpan Partners. Shareholders are expected to receive $23.50 in cash per share, and the firm is investigating whether this is a fair deal. Shareholders are encouraged to contact the firm for more information.

Surgery Partners Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surgery Partners, Inc. - SGRY

https://www.businesswire.com/news/home/20261027063875/en/Surgery-Partners-Investor-Alert-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-Surgery-Partners-Inc.---SGRY
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Surgery Partners, Inc. (NasdaqGS: SGRY) to HealthSpan Partners, where shareholders are offered $23.50 per share in cash. The law firm is examining whether this price and the process leading to the transaction are adequate or if the company is undervalued. Shareholders who believe the transaction undervalues the company are encouraged to contact KSF to discuss their legal rights.

Bon Secours affiliate makes $5.7B bid for Surgery Partners

https://www.healthcaredive.com/news/bon-secours-affiliate-5-7-billion-bid-surgery-partners/872887/
HealthSpan Partners, an investment arm of Bon Secours Mercy Health, announced a $5.7 billion bid to take outpatient surgery provider Surgery Partners private. This acquisition would integrate Surgery Partners' network of over 200 ambulatory surgery centers and multi-specialty practices across 30 states, significantly expanding Bon Secours' outpatient footprint. The deal aims to capitalize on the growing shift towards outpatient surgical care, despite Surgery Partners reporting losses last year.

Bon Secours is buying Surgery Partners for $5.7 billion

https://www.axios.com/2026/10/26/bon-secours-surgery-partners
Bon Secours Mercy Health announced its agreement to acquire Surgery Partners for approximately $5.7 billion. This acquisition will significantly expand the nonprofit health system's outpatient services, allowing patients to avoid hospital visits. The deal follows Surgery Partners' rejection of a take-private bid from Bain Capital 18 months prior.

12 Health Care Stocks Moving In Monday's Intraday Session

https://www.benzinga.com/trading-ideas/movers/26/10/62598206/12-health-care-stocks-moving-monday-s-intraday-session
This article lists 12 healthcare stocks that experienced significant price movements during Monday's intraday trading session. Six stocks, including Surgery Partners and SciSparc, saw notable gains, with Surgery Partners rising nearly 47%. Conversely, six other stocks like Cumberland Pharma and ArriVent BioPharma experienced substantial declines, with Cumberland Pharma falling over 34%.
Advertisement

McGuireWoods Provides Regulatory Counsel to HealthSpan Partners in Acquisition of Surgery Partners

https://www.mcguirewoods.com/news/press-releases/2026/10/mcguirewoods-provides-regulatory-counsel-to-healthspan-partners-in-acquisition-of-surgery-partners/
McGuireWoods served as healthcare regulatory counsel to HealthSpan Partners in its definitive agreement to acquire Surgery Partners, Inc. for approximately $5.7 billion. This transaction will create one of the nation's largest outpatient surgical care platforms, expanding HealthSpan Partners' presence and strengthening its ability to serve patients across various care settings. The deal is expected to close in the first quarter of 2027, making Surgery Partners a privately held company.

Brentwood-based Surgery Partners to go private in $5.7 billion deal

https://www.bizjournals.com/nashville/news/2026/10/26/surgery-partners-to-go-private-deal-healthspan.html
Surgery Partners, a Nashville healthcare company, is set to go private in an all-cash transaction valued at $5.7 billion. This deal will establish one of the largest outpatient surgical care platforms in the country and is anticipated to finalize next year.

Bon Secours’ HealthSpan to buy Surgery Partners in $5.7B deal

https://www.modernhealthcare.com/mergers-acquisitions/mh-bon-secours-healthspan-surgery-partners-acquisition/
Bon Secours' HealthSpan is set to acquire Surgery Partners in a $5.7 billion deal. The article, published on October 26, 2026, details this significant merger in the healthcare sector. This acquisition highlights a major transaction within the provider landscape.

Bon Secours nears $6B takeover of Surgery Partners, FT reports (SGRY:NASDAQ)

https://seekingalpha.com/news/4657004-bon-secours-nears-6b-takeover-of-surgery-partners-ft-reports
Bon Secours Mercy Health is reportedly close to acquiring a controlling stake in Surgery Partners (SGRY) for about $6 billion, including debt. This potential acquisition highlights a trend of hospital systems expanding into outpatient surgical facilities. Shareholders could see a premium on their shares following a period of decline.

Surgery Partners (SGRY) Faces Demand And Debt Pressure, Is The Stock Still Undervalued?

https://simplywall.st/stocks/us/healthcare/nasdaq-sgry/surgery-partners/news/surgery-partners-sgry-faces-demand-and-debt-pressure-is-the/amp
Surgery Partners (SGRY) is experiencing pressure from weakening procedure volumes, a projected sales decline, high net-debt-to-EBITDA, and rising interest costs, leading to investor caution despite recent short-term share price gains. The stock is considered 12% undervalued by some analysts, with a fair value of $17.95 per share, based on expectations of margin repair and disciplined execution. However, the high debt load and potential demand issues pose risks to its recovery narrative.
Advertisement

McDermott Will & Schulte advises Surgery Partners on $6B acquisition by HealthSpan Partners

https://www.mcdermottlaw.com/news/mcdermott-will-schulte-advises-surgery-partners-on-6b-acquisition-by-healthspan-partners/
McDermott Will & Schulte LLP advised Surgery Partners, Inc. on its $6 billion acquisition by HealthSpan Partners, an affiliate of Bon Secours Mercy Health. This all-cash, take-private transaction is one of the largest in the ambulatory surgery center industry's history. The acquisition will establish one of the largest outpatient surgical care platforms in the country, highlighting the ongoing strategic investment and consolidation in outpatient surgical care.

Surgery Partners, Inc. Estimates – NASDAQ:SGRY

https://www.tradingview.com/symbols/NASDAQ-SGRY/financials-estimates/
This page on TradingView provides financial estimates and actuals for Surgery Partners, Inc. (NASDAQ: SGRY). It allows users to explore reported financial data and analyst estimates across various financial statements and visualize trends over time. The platform offers comparisons of actual results with average, high, and low estimates.

Weaker Demand Might Change The Case For Investing In Surgery Partners Stock (SGRY)

https://simplywall.st/stocks/us/healthcare/nasdaq-sgry/surgery-partners/news/weaker-demand-might-change-the-case-for-investing-in-surgery
Surgery Partners (SGRY) is facing pressure due to softer procedure volumes, expected sales declines, and a high net-debt-to-EBITDA ratio, raising concerns about its financial resilience. The company's outpatient model and long-term growth initiatives are being tested as demand softens and interest costs rise, making its balance sheet a significant near-term risk. Investors are urged to consider these factors, alongside analyst forecasts and the company's projected revenue and earnings growth, to determine the stock's future potential.

Surgery Partners, Inc. Estimates – BOATS:SGRY

https://www.tradingview.com/symbols/BOATS-SGRY/financials-estimates/
This article provides an overview of Surgery Partners, Inc. (SGRY) financial data and analyst estimates, available on the TradingView platform. It allows users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform is designed for investment research, cautioning users that it is not investment advice.

Learn Why The Bull Case For Surgery Partners Stock Could Change Following Soft Demand Concerns

https://sg.finance.yahoo.com/news/learn-why-bull-case-surgery-001908354.html
Surgery Partners (SGRY), a US outpatient surgery operator, is facing challenges due to softer procedure volumes and projected sales declines, which are pressuring its business model and operating plans. High net-debt-to-EBITDA levels increase the risk of the company needing to seek new funding on less favorable terms if demand remains weak, potentially reshaping its long-term investment narrative. Analysts project revenues of US$4.0 billion and earnings of US$72.9 million by 2029, but some bearish views suggest significantly lower figures, indicating a wide range of potential outcomes.
Advertisement

Cantor Fitzgerald keeps USD 18 target for Surgery Partners stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/cantor-fitzgerald-keeps-usd-18-target-for-surgery-partners-stock/70376631
Cantor Fitzgerald has reaffirmed its "Overweight" rating and USD 18.00 price target for Surgery Partners (SGRY), indicating a potential 17.04% upside from its current Nasdaq quote. This comes as Surgery Partners reported Q2 2026 revenue of USD 848.90 million, a 4.69% increase from the previous quarter, alongside a narrowed net loss of USD 15.00 million. The company's stock was trading at USD 15.38 on Nasdaq, well within its 52-week range.

Surgery Partners (SGRY) Faces Sales And Debt Questions, Is The Stock Still Undervalued?

https://simplywall.st/stocks/us/healthcare/nasdaq-sgry/surgery-partners/news/surgery-partners-sgry-faces-sales-and-debt-questions-is-the/amp
Surgery Partners (SGRY) is facing questions regarding weakening unit sales, projected softer revenue, and a high net-debt-to-EBITDA ratio, despite recent short-term share price gains. The stock is currently trading at a discount, with analysts suggesting it is 18.6% undervalued with a fair value of $17.95 per share. The company's strategy of investing in robotics and outpatient facilities positions it for long-term growth, but potential risks include persistent anesthesia cost pressures and slower acquisition activity.

Surgery Partners stock last traded at USD 14.61 on October 16, 2026, down 1.08 percent

https://www.ad-hoc-news.de/boerse/news/nebenwerte/surgery-partners-stock-last-traded-at-usd-14-61-on-october-16-2026-down-1-08-percent/70351154
Surgery Partners (SGRY) stock closed at USD 14.61 on October 16, 2026, marking a 1.08 percent decline. The company reported second-quarter revenue of USD 848.90 million, a 2.70 percent year-over-year increase, and adjusted earnings per share of USD 0.10, surpassing consensus estimates. Despite beating revenue expectations, the company maintained a negative net margin, and its stock traded 37.67 percent below its 52-week high.

Surgery Partners (SGRY) Faces Sales And Debt Questions, Is The Stock Still Undervalued?

https://simplywall.st/stocks/us/healthcare/nasdaq-sgry/surgery-partners/news/surgery-partners-sgry-faces-sales-and-debt-questions-is-the
Surgery Partners (SGRY) is facing concerns regarding weakening unit sales, expectations for softer revenue, and a high net-debt-to-EBITDA position. Despite a recent short-term share price bounce, the stock is down 29.04% over the last year. However, Simply Wall St suggests the company is currently undervalued by about 18.6%, trading at $14.61 against a fair value of $17.95, driven by the migration of high-acuity surgical procedures to outpatient settings.

Surgery Partners stock last traded at USD 14.61 on October 16, 2026, down 1.08 percent

https://www.ad-hoc-news.de/boerse/news/nebenwerte/surgery-partners-stock-last-traded-at-usd-14-61-on-october-16-2026-down/70351154
Surgery Partners (SGRY) stock closed at USD 14.61 on October 16, 2026, marking a 1.08 percent decrease. The company reported Q2 2026 revenue of USD 848.90 million, surpassing consensus estimates, and adjusted EPS of USD 0.10, also above expectations. Despite strong revenue, the company's profitability remained negative, and its stock traded significantly below its 52-week high, with a market capitalization of USD 1.9 billion.
Advertisement

Surgery Partners stock rises 2.34 percent to EUR 13.10

https://www.ad-hoc-news.de/boerse/news/nebenwerte/surgery-partners-stock-rises-2-34-percent-to-eur-13-10/70333374
Surgery Partners stock increased by 2.34 percent to EUR 13.10 on October 15, 2026. Cantor Fitzgerald maintained an Overweight rating and an USD 18.00 price target for the company. Despite reporting a loss in adjusted earnings per share for Q2 2026, the stock showed positive movement after the Frankfurt close.

San Antonio Spine Clinic Sues Surgery Partners, Accuses Suitor of Poaching Its Doctors

https://hoodline.com/2026/10/san-antonio-spine-clinic-sues-surgery-partners-accuses-suitor-of-poaching-its-doctors/
South Texas Spinal Clinic has filed a lawsuit against Surgery Partners Inc., alleging that the company used confidential financial data obtained during acquisition talks to poach its top-earning surgeons and establish a competing practice. The clinic is seeking over $5 million in damages, accusing Surgery Partners of trade-secret misappropriation, fraud, breach of contract, tortious interference, and unfair competition. This case highlights a growing trend of physician recruitment disputes in Texas, though this specific lawsuit focuses on NDA violations and trade-secret theft rather than non-compete clauses.

Larry Robbins Opens New Position in Surgery Partners Inc (SGRY) -- Shares Look 39% Undervalued on GF Value

https://www.gurufocus.com/news/9124959/larry-robbins-opens-new-position-in-surgery-partners-inc-sgry-shares-look-39-undervalued-on-gf-value
Larry Robbins of Glenview Capital Management has opened a new position in Surgery Partners Inc (SGRY), acquiring over 7 million shares, which suggests confidence in the healthcare provider despite its "Possible Value Trap" GF Valuation label. While the stock appears 39% undervalued and has seen a short-term gain since the transaction, the company faces significant financial challenges including a low cash-to-debt ratio, negative profitability, and a high risk of financial distress. Investors are advised to exercise caution and conduct thorough due diligence due to mixed financial signals and a poor GF Score.

San Antonio spine clinic says would-be buyer used deal talks to poach doctors

https://www.expressnews.com/business/article/south-texas-spinal-clinic-surgery-partners-suit-22474702.php
South Texas Spinal Clinic has filed a lawsuit against Surgery Partners Inc., alleging the company used acquisition talks to access confidential information and then poached its top doctors to establish a competing practice. The lawsuit, seeking over $5 million in damages, accuses Surgery Partners of trade-secret misappropriation, fraud, breach of contract, tortious interference, and unfair competition. South Texas Spinal Clinic claims Surgery Partners "feigned" interest in buying the business to identify profitable aspects and then strategically lured away its most productive physicians.

A passive holder reports shared voting power over 7.02M Surgery Partners (SGRY) shares.

https://www.stocktitan.net/sec-filings/SGRY/schedule-13g-surgery-partners-inc-passive-investment-disclosure-5-218ad87cea8e.html
Glenview Capital Management, LLC and Larry Robbins have reported shared beneficial ownership of 7,023,338 shares of Surgery Partners, Inc. (SGRY), representing approximately 5.4% of the common stock outstanding. This disclosure is made through a Schedule 13G filing, indicating a passive investment. The shares are held across various Glenview funds and separately managed accounts.
Advertisement

How Declining Sales At Surgery Partners (SGRY) Has Changed Its Investment Story

https://simplywall.st/stocks/us/healthcare/nasdaq-sgry/surgery-partners/news/how-declining-sales-at-surgery-partners-sgry-has-changed-its
Surgery Partners (SGRY) is facing challenges due to declining sales, rising interest costs on floating-rate debt, and a high net-debt-to-EBITDA ratio. These factors are raising concerns about the company's ability to deleverage and could potentially lead to shareholder dilution. While some models suggest an undervaluation based on future cash flow, this depends heavily on the company's ability to stabilize sales, manage costs, and navigate a pressured payer mix.

McDermott Will & Schulte advises Surgery Partners on sale of ownership interests in Idaho Falls facilities

https://www.mcdermottlaw.com/news/mcdermott-will-schulte-advises-surgery-partners-on-sale-of-ownership-interests-in-idaho-falls-facilities/
McDermott Will & Schulte advised Surgery Partners (NASDAQ: SGRY) on the sale of its majority ownership interest in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health. The transaction, valued at approximately $1.15 billion, with Surgery Partners receiving about $797 million in gross proceeds, marks a significant step in Surgery Partners' portfolio optimization strategy. This complex deal involved multiple stakeholders and significant antitrust and healthcare regulatory considerations.

Surgery Partners stock gains 2.24 percent with Cantor at Overweight

https://www.ad-hoc-news.de/boerse/news/nebenwerte/surgery-partners-stock-gains-2-24-percent-with-cantor-at-overweight/70260474
Surgery Partners stock gained 2.24% on October 7, 2026, after Cantor Fitzgerald reiterated an Overweight rating and a USD 18.00 price target. Despite revenue beating forecasts in Q2 2026, the company reported an adjusted loss, leading to a mixed operating picture. Analysts maintain a "Moderate Buy" consensus with an average price target of USD 19.00, significantly above its current market price.

Cantor Fitzgerald reiterates Surgery Partners stock Overweight rating By Investing.com

https://ng.investing.com/news/stock-market-news/cantor-fitzgerald-reiterates-surgery-partners-stock-overweight-rating-93CH-2723593
Cantor Fitzgerald has reiterated its Overweight rating on Surgery Partners (NASDAQ: SGRY) with an $18.00 price target, suggesting a 35% upside despite a recent 35% stock decline. Analysts project profitability for SGRY this year, with expected earnings of $0.32 per share. The company is not experiencing staffing shortages, and recent data indicates stable ambulatory surgery center openings and a decrease in average bonus payments.

RBC reiterates target for Surgery Partners stock at USD 19.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/rbc-reiterates-target-for-surgery-partners-stock-at-usd-19-00/70247982
RBC Capital has reiterated its Outperform rating for Surgery Partners (SGRY) stock, setting a price target of USD 19.00. This follows Surgery Partners' recent sale of interests in two Idaho hospitals, generating USD 587 million in net cash proceeds primarily intended for debt reduction. The divestiture led to a revised 2026 revenue guidance of USD 3.08-3.18 billion and adjusted EBITDA of at least USD 489 million, reflecting a more focused operating portfolio despite a lower consolidated scale.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement